Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft

AIDS

Volumn 27, Issue 16, 2013, Pages 2655-2657

  Antonini, Teresa M ^a,b   Furlan, Valerie ^a,d   Teicher, Elina ^a,e   Haim Boukobza, Stephanie ^a,b,c   Sebagh, Mylene ^a,b,c   Coilly, Audrey ^a,b,c   Bonhomme Faivre, Laurence ^a   Peytavin, Gilles ^f,g   Roque Afonso, Anne Marie ^a,b,c   Vittecoq, Daniel ^a,e   Samuel, Didier ^a,b,c   Taburet, Anne Marie ^a,d   Duclos Vallée, Jean Charles ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Universite Paris Sud   (France)

^d Pharmacie Clinique   (France)

^e BICÊTRE HOSPITAL   (France)

^f AP HP GH Xavier Bichat Claude Bernard   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; BOCEPREVIR; CORTICOSTEROID; CYCLOSPORIN; DARUNAVIR; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; TACROLIMUS; TELAPREVIR; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GINGIVA HYPERPLASIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRICHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TRANSPLANTATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84885430110     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432539.77711.f4     Document Type: Article

References (13)

1. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13:150-157.
2. Duclos-Vallée JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-417.
3. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716-726.
4. Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Aguero F, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012; 12:1866-1876.
5. Antonini TM, Sebagh M, Roque-Afonso AM, Teicher E, Roche B, Sobesky R, et al. Fibrosing cholestatic hepatitis in HIV/HCV coinfected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011; 11:1686-1695.
6. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
7. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
8. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6:3-16.
9. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
10. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-1470.
11. Coilly A, Furlan V, Roche B, Barau C, Noël C, Bonhomme-Faivre L, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56:5728-5734.
12. Häim-Boukobza S, Balabanian K, Teicher E, Bourgeade M, Perlemuter G, Roque-Afonso AM, Duclos-Vallee JC. Blockade of CCR5 to protect the liver graft in HIV/HCV coinfected patients. J Hepatol 2013; pii: S0168-8278(13)00216-X. doi: 10.1016/j.jhep.2013.03.034. [Epub ahead of print].
13. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11:179-185.